Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic ex vivo expanded NK cell therapy for metastatic breast cancer
IRCT20200621047859N1Phase 2Completed
- Sponsor
- Motamed Cancer Institute
- Start
- Aug 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and fludarabine in breast cancer, sponsored by Motamed Cancer Institute. Primary endpoints: Hypersensitivity and allergy, Tumor size changes and secondary metastases and 1 more. Started Aug 2020; status: completed.
02
Drugs
cyclophosphamidefludarabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20200621047859N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200621047859N1.